Alcoholic liver disease (ALD), TNF-alpha and the putative therapeutic effect of palmitoylethanolamide

PEA inhibits the negative effects of TNF-alpha

PEA inhibits the negative effects of TNF-alpha

A patient suffering from a chronic Alcoholic liver disease (ALD) was treated with palmitoylethanolamide. He reported much increase in his vitality and stamina as well as a positive effect on ADL. We perhaps can understand this effect by palmitoylethanolamide inhibitory functions on inflammation and cytokines such as TNF-alpha.  Enhanced inflammation in the liver during ethanol exposure is a major feature of ALD.

 The pro-inflammatory cytokine tumornecrosis factor (TNF-α) has been demonstrated to be one of the key factors in the various aspects of pathophysiology of ALD.

This quote is from Cytokines in alcoholic liver disease, a recent review article.

Interactions between pro- and anti-inflammatory cytokines such as TNFα and adiponectin and other cytokines are likely to play important roles in the development and progression of alcoholic liver disease, according to the authors.

Palmitoylethanolamide is a known inhibitor of TNF-alpha as well as a modulator of other inflammatory cytokines.

Source: An L, Wang X, Cederbaum AI. Cytokines in alcoholic liver disease.Arch Toxicol. 2012 Sep;86(9):1337-48. doi: 10.1007/s00204-012-0814-6. Epub 2012 Feb 25.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: